- In March 2026, Illumina and Labcorp expanded their precision oncology collaboration to develop and distribute next-generation sequencing-based cancer tests, including co-commercializing Labcorp's FDA-authorized PGDx elio plasma focus Dx liquid biopsy alongside Illumina's FDA-approved TruSight Oncology Comprehensive for solid tumors.
- This alliance aims to widen access to both tissue and liquid biopsy biomarker testing, support companion diagnostic development for drugmakers, and strengthen evidence for payer coverage of comprehensive genomic profiling and whole-genome sequencing in cancer care.
- We’ll now examine how this expanded Illumina partnership, particularly the co-commercialization of tissue and liquid biopsy test kits, may influence Labcorp’s investment narrative.
The latest GPUs need a type of rare earth metal called Neodymium and there are only 26 companies in the world exploring or producing it. Find the list for free.
Labcorp Holdings Investment Narrative Recap
To own Labcorp, you need to believe its scale in diagnostics and biopharma lab services can keep attracting volume even as pricing and regulatory pressures persist. The Illumina expansion strengthens its oncology testing franchise, but does not meaningfully change near term sensitivity to reimbursement shifts such as PAMA or broader macro and FX headwinds.
The most relevant recent announcement is Labcorp’s 2026 revenue guidance of US$14.61 billion to US$14.79 billion, which frames expectations around mid single digit growth. The Illumina collaboration fits within this longer running push to expand higher value oncology and genomic testing, a category that already sits at the center of Labcorp’s new test and partnership pipeline.
Yet, beneath the appeal of expanded cancer testing access, investors should still be aware of the potential impact of...
Read the full narrative on Labcorp Holdings (it's free!)
Labcorp Holdings' narrative projects $15.6 billion revenue and $1.3 billion earnings by 2028.
Uncover how Labcorp Holdings' forecasts yield a $307.71 fair value, a 15% upside to its current price.
Exploring Other Perspectives
Four members of the Simply Wall St Community value Labcorp between US$200 and about US$390 per share, reflecting a wide spread of expectations. When you weigh those views against the key risk of tariff and regulatory driven cost pressures, it underlines why many investors look at several contrasting scenarios before forming an opinion.
Explore 4 other fair value estimates on Labcorp Holdings - why the stock might be worth 25% less than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Labcorp Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Labcorp Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Labcorp Holdings' overall financial health at a glance.
Contemplating Other Strategies?
Our top stock finds are flying under the radar-for now. Get in early:
- Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com